TAG Masterclass: Long Term US Investor

As part of our TAG Masterclass Series we are delighted to welcome Fiona Marshall, VP Head of Discovery Research UK, MSD for an executive roundtable discussion on the development of their new Discovery Centre in London’s King’s Cross and the future of the UK investment landscape

U.S. Pharmaceutical group MSD recently announced that, subject to planning approval, their new London Discovery Research Centre will be located in London’s “Knowledge Quarter,” Kings Cross. The new 220,000-square-foot research facility will be home to a total of 800 employees and is expected to be completed by 2025.
David Peacock, MSD’s Managing Director for the UK sees the UK “as a world leader in scientific development, driven by a long-term emphasis on building a strong research and development infrastructure” and the investment demonstrates a firm commitment by MSD to the UK’s life sciences sector. The UK hub will be MSD’s first set of labs outside the US that will carry out early-stage research to discover new medicines.
Fiona Marshall, Vice President, head of neuroscience and head of discovery research for MSD in the UK will discuss this expansion project and the opportunities for further inward investment in the UK.
The discussion will also consider the impact of COVID-19 on investment strategies and future growth, as well as the leadership and health challenges the pandemic has created and what companies can do to overcome and adapt in this current environment.


MSD is a multinational pharmaceutical company providing medicines and vaccines for some of the world’s most challenging conditions.
MSD are at the forefront of some of the world’s most urgent global health challenges, including cancer, hepatitis C, antibiotic resistance, Alzheimer’s disease, Ebola, heart disease and more. In the UK alone, last year they reached over 3 million people through our vaccines. Their Animal Health division offers one of the industry’s most innovative portfolios to prevent, treat and control diseases across all major farm and companion animal species.
For more than 125 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives.


Fiona Marshall, VP Head of Discovery Research UK, MSD

Fiona joined MSD in 2018 as VP Head of Discovery Research UK and has since taken on the additional role of Global Head of Neuroscience Discovery. She has more than 25 years’ experience in drug discovery and development across Pharma and Biotech companies. Previously Fiona was VP and CSO of the Japanese Biotech company Sosei Group which acquired Heptares Therapeutics in 2015. Fiona was a founder and Chief Scientific Officer of Heptares Therapeutics a highly successful UK Biotech company focussed on structure-based drug discovery. Prior to that she was European Head of Discovery Biology for Millennium Pharmaceuticals and before that held senior positions in GSK.

Fiona is on the council of the Academy of Medical sciences and on advisory boards of the Medical Research Council, the Francis Crick Institute and the Wellcome Trust. She won the 2012 WISE Women of Outstanding Achievement for Innovation and Entrepreneurship and the 2015 RSC Malcolm Campbell Award for chemistry, the 2018 John Vane medal and the 2018 Astra Zeneca Prize for Women in Pharmacology. She is a Fellow of the British Pharmacological Society and the Academy of Medical Sciences and an Honorary Fellow of the Royal Society of Chemistry.

Fiona is renowned for her work on G protein-coupled receptors (GPCRs) and has published extensively in the field.   She has a BSc in biochemistry from Bath University and a PhD in neuroscience from Cambridge University.



 Wednesday 28th October


4.00 pm – 5:00 pm GMT / 12.00 pm – 1.00 pm EDT


Zoom – Link will be provided for registered guests